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Abstract
A clinical audit of hospitals in Thailand was conducted to assess compliance with the 
national hypertension treatment guidelines and determine hypertension control rates 
across facilities of different sizes. Stratified random sampling was used to select six-
teen hospitals of different sizes from four provinces. These included community (<90 
beds), large (90–120 beds), and provincial (>120 beds) hospitals. Among new cases, the 
audit determined whether (i) the recommended baseline laboratory assessment was 
completed, (ii) the initial choice of medication was appropriate based on the patient's 
cardiovascular risk, and (iii) patients received medication adjustments when indicated. 
The hypertension control rates at six months and at the last visit were recorded. 
Among the 1406 patients, about 75% had their baseline glucose and kidney function 
assessed. Nearly 30% (n = 425/1406) of patients were indicated for dual therapy but 
only 43% of them (n = 182/425) received this. During treatment, 28% (198/1406) re-
quired adjustments in medication but this was not done. The control of hypertension 
at six months after treatment initiation was 53% varying between 51% in community 
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1  |  INTRODUC TION
Cardiovascular disease (CVD) was the leading cause of mortality in 
Thailand 2017.1 The burden of hypertension in Thailand, usually de-
fined as systolic blood pressure of at least 140mmHg or diastolic 
blood pressure of at least 90 mmHg or on medication to lower 
blood pressure, is a major risk for CVD, remains high with a prev-
alence of one in four adults.2,3 According to the Ministry of Public 
Health (MoPH) of Thailand, the number of people registered for 
hypertension treatment has risen from nearly 4 million in 2013 to 
over 5.5 million in 2017.4 The health system in Thailand has evolved 
to adapt to the population dynamics and disease epidemiology 
geared toward the aging population and epidemiological transition 
toward non-communicable diseases.5 Since achieving universal 
health coverage (UHC) in 2002, and also with the incorporation of 
antihypertensive drugs into the benefits package of UHC in 2011, 
the awareness and coverage of hypertension screening services in 
Thailand reached 55% by 2013.3,6
Introduction of the updated Thai hypertension clinical prac-
tice guidelines in 2015 was a major move to improve hypertension 
care.7 Among other things, these guidelines provide: recommenda-
tions on cardiovascular risk stratification based on 10-year risk of 
CVD mortality; list of assessments required to identify subclinical 
organ damage; detailed strategies for using combination strategy if 
patients have high (CVD mortality risk 5%–10%) to very high CVD 
mortality risk (>10%); and a stepped approach to blood pressure 
monitoring for patients in different risks groups. However, despite 
these advances, population-based surveys have suggested that the 
overall hypertension control among Thai patients is still at 30%, with 
varying capacity to diagnose and treat hypertension at the hospi-
tal level across different provinces of Thailand.8,9 This may be due 
to poor adherence to suggested treatment guidelines. A recent re-
view in Hong Kong showed that only 11% of patients received a car-
diovascular disease (CVD) risk assessment at diagnosis, 10 while a 
study in Romania found that 30% did not receive drug adherence 
counseling.11
Another reason for suboptimal control rates in Thailand may be 
attributable to how the hypertension services are organized and de-
livered at the different levels of care (primary, secondary, and ter-
tiary care) across different levels of treatment facilities (community 
hospitals and provincial hospitals).3,8 With the development of the 
universal health coverage plan, all Thai citizens have access to health 
care which has reduced inequalities across Thailand.5,12,13 Over 85% 
of all outpatient visits in Thailand are provided by public hospitals 
which has a strong network of two-way referrals between provin-
cial hospitals, community hospitals, and health centers.8 Most new 
patients with hypertension are diagnosed at the community hos-
pitals by physicians. While hypertension is treatable at all levels of 
care and in both community and provincial hospitals, the initiation 
of treatment in uncomplicated cases is usually at primary care level 
in community hospitals. Complex cases with other uncontrolled 
co-morbidities or cases with signs and symptoms of cardiovascular 
complications at diagnosis are usually treated by internists or spe-
cialists at secondary care level in bigger provincial hospitals. Thus, 
patients treated at smaller community hospitals generally have eas-
ier access to the providers and are usually cared for by primary care 
physicians and nurses. Patients who are treated at larger provincial 
Thai hospitals and referral hospitals generally have easier access 
to specialists when needed, but may face longer waiting times and 
shorter contact time. These issues may affect the delivery of hyper-
tension care and control rates.14
Clinical audits are useful to help assess consistency between 
guideline recommendations and actual practice.15,16 In this current 
study, an audit of Thai hospitals was conducted to (i) identify gaps 
between actual practice and the recommended practice as proposed 
by the Thai Hypertension Guideline and (ii) to identify variations in 
compliance of standard treatment guidelines and rate of hyperten-
sion control between hospitals of different sizes. Understanding 
these gaps and variations may improve hypertension care as seen in 
Canada where hypertension control significantly improved to over 
70%.17
2  |  METHODS
2.1  |  Study design
New hypertensive patients are usually registered into a hospi-
tal's record system if they have two high blood pressure readings 
(≥140/90 mmHg) at least two weeks apart or are referred for treat-
ment from another hospital. An audit of these newly diagnosed/
registered patients entering treatment was conducted among 16 
hospitals across four Thai regions (North, Central, Northeast, and 
South). Within each region, a province was randomly selected. The 
probability assigned to each province was proportionate to the size 
of the population in each region. Within each province, hospitals 
and 56% in large hospitals (p < .01). The hypertension control rate at last visit was 64% 
but varied between 59% in community hospitals and 71% in large hospitals (p < .01). 
Failure to adjust medication when required was associated with 30% decrease in the 
odds of hypertension control (OR 0.69, 95% CI 0. 50 to 0.90). Failure to comply with 
the treatment guidelines regarding adjustment of medication and lost to follow-up are 
possible target areas to improve hypertension control in Thailand.
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were stratified according to the size of the hospital. One provincial/
referral hospital (>120 beds), one large hospital (90–120 beds), and 
two small community hospitals (<90 beds) were then randomly se-
lected from each province using a random number generator. Within 
each hospital, researchers sequentially reviewed records of at least 
70 consecutively enrolled newly registered patients with start date 
from January 1, 2017, onwards and audited their clinical records up 
to 30 June 2018. For all patients in the clinics, health care including 
laboratory investigations and medication are covered by the govern-
ment through either the universal coverage scheme, social security 
scheme or civil servant medical benefit scheme.8
2.2  |  Audit tools
A standard tool designed from the 2015 Thai National guidelines for 
Hypertension was used to collect data from newly registered hyper-
tensive patients receiving care in the 16 hospitals. In addition to re-
cording age, sex, weight, height, and history of co-morbidities, each 
patient record was assessed in three main areas regarding hyperten-
sion treatment (i) initial clinical and laboratory assessment, (ii) medi-
cation prescription and adjustment, and (iii) treatment outcomes.
1. Initial assessment: Data were collected on whether patients 
had all the recommended laboratory investigations within three 
months of diagnosis and/or registration as a hypertensive patient. 
According to the Thai Hypertension Guideline, this includes a 
baseline fasting blood glucose, full lipid profile, serum creati-
nine, serum potassium (K), serum sodium (Na), urine analysis, 
urine microalbuminuria, and EKG. In addition, the audit assessed 
whether the 10-year risk of cardiovascular death (or CVD risk 
score) was documented.
2. Medication prescription and adjustment: The audit assessed 
whether the patients started on the recommended therapy (mon-
otherapy or dual therapy) based on their ten-year CVD mortality 
risk and baseline laboratory results. Based on the Thai CVD risk 
score, the Thai hypertension treatment guidelines suggest the use 
of more than one medication if the overall CVD risk of mortality 
is at least 5%. If the Thai CVD risk score was not documented 
in the medical records, this was calculated by the research team 
according to age, sex, history of smoking, and co-morbidities 
such as diabetes and high cholesterol.18 Patients were then as-
sessed whether they had their medication adjusted if their blood 
pressure was not under control. Information was also collected 
on whether fixed dose combination pills were used for those re-
quiring more than one medication. Inappropriate medication ad-
justments were also assessed. This was defined according to any 
one of the following two scenarios: (i) inappropriate medication 
adjustment such as failure to increase medication and (ii) incor-
rect medication adjustment such as changed medication but no 
clear advantage in terms of side effects such as switching from 
one ACEI to another ACEI rather than another class of medication 
such as ARBs.
3. Treatment outcomes: Retention rate in treatment at 6 months 
(−30/+90 days), rate of hypertension control at 6 months, and at 
last reading at the time of the audit (within 12 months after treat-
ment) was recorded.
2.3  |  Data analysis
Descriptive statistics were used to describe patient demographics, 
initial presentation, and treatment received. Variations in compli-
ance of standard treatment guidelines across different hospital sizes 
and rate of hypertension control were tested using ANOVA or chi-
square. The rate of hypertension control at six months and at the last 
visit was calculated by dividing the number of patients who obtained 
a systolic blood pressure (SBP) < 140 mmHg and diastolic blood pres-
sure (DBP) < 90 mmHg by the total number of patients included. 95% 
confidence intervals (CIs) were estimated using logistic regression. In 
addition, to determine whether factors associated with hypertension 
control at last visit, three multivariable logistic regression models 
were used. Model 1 explored heath systems and environment fac-
tors by including hospital size and region (North, Central, Northeast, 
and South) as explanatory variables. Model 2 included patient-related 
factors (age, sex, baseline CVD risk) as additional exploratory vari-
ables to Model 1. The last full model, Model 3, included treatment-
related factors (inappropriate medication at initiation of treatment, 
inappropriate medication adjustment, and number of medications) as 
additional exploratory variables. This sequential modeling strategy 
can help identified whether potential variations between hospital 
sizes were confounded by different geographic- and patient-related 
factors. In addition, it will help identify aspects of treatment that may 
be beneficial to hypertension control while adjusting for patient, hos-
pital, and environmental factors. Using the same sequential modeling 
strategy, a sensitivity analysis was conducted to explore factors as-
sociated with loss to follow-up at 6 months as loss to follow-up may 
be one of the key contributing factors to hypertension control.
2.4  |  Ethics
This was a retrospective audit of routine clinical records. Patient 
consent was not required and ethical approval to conduct the audit 
was approved by The Faculty of Medicine, Chiang Mai University 
(No 151/2018).
3  |  RESULTS
3.1  |  Characterization of newly diagnosed/
registered hypertensive patients
In all, 1406 cases of newly diagnosed/registered hypertension were 
reviewed. The mean age of the patients was 58 years (SD ± 13) of 
whom 56% were females. The mean BP was 157/90 mmHg. Almost 
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10% had a previous diagnosis of hypertension from another hospital. 
The majority of patients had co-morbidities including dyslipidemia, 
diabetes, chronic kidney disease, or CVDs (Table 1). The demo-
graphic characteristics (age and sex) of patients did not significantly 
differ by type of hospitals, but patients registered to treatment in 
provincial hospitals had higher proportions with obesity (51%) and 
co-morbidities (74%) compared to those registered at commu-
nity hospitals where 42% were obese and 54% had co-morbidities 
(Table 1).
3.2  |  Initial assessment
At initial assessment, only half of all patients had their ten-year CVD 
risk assessment calculated and recorded (Table 2). The majority 
(>75%) had their glucose, lipid profile, and kidney function assessed 
within three months of diagnosis. Although recommended for all pa-
tients at initial assessment, only 12% had an EKG and 10% had their 
urine tested for microalbuminuria.
3.3  |  Medication prescription and adjustment
Over half of the hypertension patients (791/1406) were at least 
at moderate risk for developing CVDs. Over 30% of the patients 
(425/1406) were recommended dual antihypertensive therapy ac-
cording to the national guideline (due to 10-year CVD risk ≥ 5%), but 
only 43% (182/425) of these patients received dual therapy. The most 
commonly prescribed medications for hypertension management 
were calcium channel blockers (68%) and angiotensin-converting 
TA B L E  1  Baseline demographics of patients newly diagnosed/registered with hypertension entering treatment by size of hospitals
Total (n = 1406)
Provincial (>120 beds) 
(n = 280)
Large (90–120 beds) 
(n = 456)
Community (<90 beds) 
(n = 670) p-value
Sex: Male (column %) 44.2 41.8 45.2 44.5 .65
Baseline mean age years 
(SD)
58.4 (13.0) 57.0 (11.9) 59.0 (13.3) 58.5 (13.1) .12
Blood pressure at baseline
Mean SBP mmHg (SD) 157.1 (22.2) 155.5 (24.9) 158.0 (22.3) 157.2 (21.0) <.01
Mean DBP mmHg (SD) 90.1 (15.3) 89.8 (18.8) 91.5 (13.9) 89.4 (14.6) <.01
Age group in years (column %)
<30 1.4 0.7 1.3 1.6 .23
30–40 6.8 8.2 6.1 6.7
40–50 20.6 18.6 22.8 19.8
50–60 27.5 32.9 24.1 27.5
60–70 26.6 26.4 26.3 26.9
70+ 17.2 13.2 19.3 17.5
BMI category in kg/m2 (column %)
Underweight (<18.5) 6.3 4.1 8.0 6.0 .05
Normal (18.5 to < 23) 27.4 21.7 27.2 29.7
At risk (23 to < 25) 20.8 22.9 18.9 21.2
Obese I (25 to < 30) 32.7 38.8 31.4 30.9
Obese II (≥30) 12.8 11.5 14.5 12.2
Co-morbidity (column %)
None 35.6 25.7 27.0 45.8 <.01
Diabetes 12.4 17.1 11.0 11.3 .03
Chronic kidney disease 5.6 6.4 6.1 4.8 .48
Cardiovascular diseases 4.8 6.4 4.2 4.6 .36
Dyslipidemia 40.1 48.6 48.9 30.6 <.01
Smoking (column %)
Not recorded 4.0 5.4 3.3 4.0 <.01
None 77.9 78.9 72.6 81.0
Ex-smoker 8.3 9.3 14.0 4.0
Current smoker 9.7 6.4 10.1 10.9
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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enzyme inhibitors (36%). At the initiation of treatment, the propor-
tion receiving appropriate medication (monotherapy or dual therapy) 
were 53% (242/456), 42.5% (119/280), and 40% (270/670) among 
the large hospitals, provincial hospitals, and community hospitals, 
respectively (p < .01) (Table 3). About 26% (365/1406) of patients 
were able to achieve BP control without needing further dose adjust-
ments and about 40% (564/1406) received dose adjustments when 
required. During treatment, about 28% (398/1406) of patients re-
quired adjustments in medication but did not receive it. At the end of 
the year, 59% of patients were prescribed monotherapy (822/1403). 
Only one person was prescribed a single-pill combination.
3.4  |  Treatment outcomes
For treatment outcomes, 8.7% were completely lost to follow-up 
by 6 months, varying between 3.5% at large hospitals and 12.5% at 
community hospitals (Table 4). The median follow-up time at the last 
visit was 355 days (IQR 231 to 449). Overall, 52.8% (95%CI 50.2 to 
55.5) of patients had their hypertension controlled at six months and 
64.1% (95%CI 61.6 to 66.6) at last visit. For hypertension control at 
last reading, 71% (95% CI 66.9 to 75.2) of patients receiving care at 
large hospitals had their BP under control at their last visit while 65% 
(95% CI 59.4 to 70.6) of patients had their BP under control during 
their last visit at provincial hospitals and 59% (95% CI 55.2 to 62.7) 
of patients at community hospitals (p < .01) (Figure 1).
3.5  |  Factors associated with hypertension control
The variations in hypertension control rate were still significant de-
spite adjusting for geographic factors (Table 5 Model 1). When patient-
related factors were included in the model, data suggested that very 
old age and female sex were significantly associated with hypertension 
control (Table 5 Model 2). Hypertension control varied by hospital size 
(p = .03 and region (p < .01)) despite adjusting for patient-related fac-
tors. For treatment-related factors (Table 5 Model 3), patients who did 
not received appropriate medication adjustments were 31% less likely 
to have their hypertension controlled (OR 0.69, 95% CI 0.53 to 0.90, 
p < .01), whereas appropriate medication initially did not increase the 
likeliness of hypertension control. In addition, those with uncontrolled 
hypertension were more likely to be on more than one medication. The 
odds ratio for hypertension control was 0.66 for those with more than 
one medication (95% CI 0.51 to 0.85, p < .01).
Sensitivity analysis exploring factors associated with loss to fol-
low-up at 6 months found similar patterns to hypertension control. 
TA B L E  2  Initial presentation and baseline assessment of patients newly diagnosed/registered with hypertension entering treatment by 
size of hospitals
Total (n = 1406)
Provincial (>120 beds) 
(n = 280)
Large (90–120 beds) 
(n = 456)
Community (<90 
beds) (n = 670) p-value*
Treatment type (%)
New 88.3 82.1 92.7 87.9 <.01
Referral from other hospitals 10.7 17.9 7.3 12.1
New cases from screening program 
(%)
12.2 9.3 12.9 12.9 .25
Cardiovascular risk score assesseda  
(%)
51.8 26.3 49.7 63.7 <.01
Receiving baseline assessment recommended by national hypertension guideline at first visit (within 3 months) (%)
Fasting blood glucose 76.6 71.2 83.3 74.1 <.01
Total cholesterol 69.5 68.8 64.7 72.9 .01
HDL 67.3 67.0 63.2 70.2 .04
LDL 74.1 69.6 81.8 70.7 <.01
Triglyceride 74.7 71.0 82.5 70.8 <.01
eGFR 74.7 72.5 85.5 68.3 <.01
Serum potassium 38.5 54.0 47.6 25.9 <.01
Serum sodium 35.5 50.2 46.5 21.9 <.01
Urinalysis 26.7 40.4 28.9 19.5 <.01
Urine microalbuminuria 10.0 5.8 18.4 6.0 <.01
EKG 12.3 32.4 9.9 5.7 <.01
Abbreviations: eGFR, estimated glomerular filtration rate; EKG, electrocardiogram; HDL, high-density lipoprotein cholesterol; LDL, low-density 
lipoprotein cholesterol.
aThose with already established CVD are excluded from the calculations 
*Chi-square p-value. 
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Adjusting for geographic variations, large hospitals had the lowest 
proportion of loss to follow-up, while small community hospitals had 
the highest proportion of loss to follow-up and provincial hospitals 
had the intermediate risk of loss to follow-up (Table S1 model 1 and 
Figure S1). No other patient-related factors (Table S1 Model 2) or 
treatment factors (Table S1 Model 3) were significantly associated 
to loss to follow-up.
4  |  DISCUSSION
About 30% of new patients registered for treatment, irrespective 
of the size of the hospitals, were already at high risk of CVD mor-
tality. Almost ten percent of newly diagnosed patients were lost 
to follow-up and around two thirds of newly diagnosed cases had 
their blood pressure controlled during their last visit to the hospital. 
TA B L E  3  Hypertension treatment of patients newly diagnosed/registered with hypertension entering treatment by size of hospitals
Total (n = 1406)
Provincial (>120 beds) 
(n = 280)
Large (90–120 beds) 
(n = 456)
Community (<90 beds) 
(n = 670) p-value
Cardiovascular disease (CVD) mortality risk based on audit
Can't calculate 4.9 5.0 4.8 4.9 .17
Low (CVD risk < 1) 38.8 45.0 36.8 37.6
Moderate (CVD risk 1 
to ≤ 5)
26.0 25.4 24.5 27.3
High (CVD > 5%) 30.2 24.6 33.8 30.2
Choice of medication based on risk assessment (initial BP and CVD risk)




35.0 32.5 41.9 31.3 <.01
Appropriate start of duo 
therapy when duo 
therapy indicateda  (%)
9.9 10.0 11.2 9.0
Inappropriate (%) 55.1 57.5 46.9 59.7
First-line medication used
Thiazide-type diuretic (%) 6.5 6.1 4.2 8.2 .03
CCBs (%) 67.6 67.1 77.0 61.3 <.01
ACEIs (%) 35.9 27.1 32.9 41.3 <.01
ARBs (%) 3.7 8.2 2.2 2.8 <.01
Dose adjustments when required (uncontrol or presented with side effects)
Good control at all visits (no 
adjustment required) 
(%)
26.0 28.2 25.0 25.7 .27
Appropriate adjustment (%) 40.1 41.4 43.0 37.6
Inappropriate adjustmentb  
(%)
1.1 0.4 1.7 1.0
No adjustment throughout 
(with some visits 
uncontrolled) (%)
28.3 26.8 25.9 30.6
Incomplete data to evaluate 
(%)
4.5 3.1 4.4 5.1
Treatment regimen prescribed
Monotherapy (%) 58.6 51.1 54.5 64.5 <.01
Multiple pill combination 
therapy (%)
41.3 48.9 45.3 35.5
Single-pill combination 
therapy (%)
0.1 0 0.2 0
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; CCB, calcium channel blocker.
aThai guideline suggests dual therapy if at high risk. 
bIn appropriate adjustment defined as at least one of the two scenarios occurring: (1) inappropriate medication adjustment such as failure to increase 
medication and (2) incorrect medication adjustment such as changed medication but no clear advantage. 
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In addition, more than a quarter of the patients did not get correct 
medication adjustment despite being indicated for it over the period 
of evaluation.
Our findings are in-line with previous studies where CCBs are 
the most commonly used antihypertensive medication, while diuret-
ics are less commonly used.14,19,20 This is likely due to the 2011 Asian 
Pacific Heart Associations’ recommendation for CCBs to be the pre-
ferred drug for managing hypertension in East Asian countries,21 
while the use of diuresis is usually avoided due to the expected 
problems with diuresis and the need to monitor serum potassium. 
This is also reflected in our result where only about one-third had 
their serum potassium assessed. In addition, urine albumin creati-
nine ratio (UACR) is suggested as a baseline assessment especially 
for those with diabetes or CKD, but was only assessed in 10% of 
participants. This investigation is not routinely available and usually 
only done if impaired renal function is detected via eGFR. A national 
study published in 2020 also found that only about 10% of patients 
with diabetes had UACR tested in the past year.22 The low preva-
lence of ARBs is likely due to the fact that only one ARB is included 
in the Thai National list of essential drugs and is more expensive 
TA B L E  4  Hypertension control by size of hospitals
Total (n = 1406)
Provincial (>120 beds) 
(n = 280)
Large (90–120 beds) 
(n = 456)
Community (<90 
beds) (n = 670) p-value
Follow-up status (column %)
Loss to follow-up after diagnosis 0.8 0.4 0.4 1.2 <.01
Loss before 6 months of 
treatment
7.9 7.5 3.1 11.3
Completed 6 months follow-up 91.3 92.1 96.5 87.5
Hypertension control control at 6 months (−30/+90 days after treatment) (column %)
Loss to follow-up after diagnosis 0.8 0.4 0.4 1.2 <.01
Loss to follow-up before 6 months 7.9 7.5 3.1 11.3
No reading at 6 months 9.1 10.4 11.0 7.3
Uncontrolled hypertension at 
6 months
29.4 30.4 29.4 29.0
Controlled at 6 months 52.8 51.4 56.1 51.2
Hypertension control (last readinga ) (column %)
Loss to follow-up after diagnosis 0.8 0.4 0.4 1.2 <.01
Loss to follow-up before 6 months 7.9 7.5 3.1 11.3
Uncontrol hypertension at last 
visit
27.2 27.1 25.4 28.5
Control hypertension at last visit 64.1 65.0 71.0 59.0
aLast reading: average follow time 342 days (SD ± 129 days), median follow-up time 355 days (IQR 231 to 449). 
F I G U R E  1  Hypertension control rates 
by size of hospitals
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TA B L E  5  factors associated with hypertension control at last visit
Model 1 Model 2 Model 3
OR hypertension control at 
last visit (95%CI) p-value
OR hypertension control 
at last visit p-value
OR hypertension control 
at last visit p-value




Reference .03 Reference .03 Reference <0.01
Large (90–120 
beds)
1.21(0.87 to 1.69, p = .25) 1.18 (0.83 to 1.67, 
p = .35)




0.68 (0.60 to 1.10), p = .18 0.79 (0.58 to 1.08, 
p = .14)
0.78 (0.56 to 1.08, 
p = .13)
Region
North Reference <.01 Reference <.01 Reference <.01
South 0.61(0.45 to 0.84, p < .01) 0.54 (0.40 to 0.76, 
p < .01)
0.55 (0.39 to 0.78, 
p < .01)
Central 1.06 (0.76 to 1.48, p = .72) 0.93 (0.66 to 1.31, 
p = .68)
0.95 (0.66 to 1.37, 
p = .77)
Northeast 0.68 (0.49 to 0.94, p = .02) 0.59 (p = .42 to 0.83, 
p < .01)




<30 Reference .07 Reference .04
30–40 2.46 (0.84 to 7.16), p = .10 2.93 (0.90 to 9.54, 
p = .08)
41–50 2.31 (0.84 to 6.32), 
p = .10
2.66 (0.87 to 8.18, 
p = .09)
51–60 1.84 (0.67 to 5.08), 
p = .23
1.91 (0.62 to 5.90, 
p = .26)
61–70 2.20 (0.77 to 6.25, 
p = .14)
2.28 (0.71 to 7.29, 
p = .16)
>70 3.20 (1.09 to 9.42, 
p = .03)
3.35 (1.02 to 11.0, 
p = .05)
Sex
Male Reference .05 Reference .04
Female 1.26 (1.00 to 1.61, 
p = .05)
1.29 (1.01 to 1.65, 
p = .04)
Baseline CVD risk
Low Reference .29 Reference .35
Moderate 0.77 (0.54 to 1.08, 
p = .13)
0.80 (0.56 to 1.15, 
p = .23)
High 0.88 (0.58 to 1.32, 
p = .53)









Inappropriatec  0.69 (0.53 to 0.90, p < .01
(Continues)
    |  9ANGKURAWARANON et Al.
compared to ACEIs.23 Combined pills are not yet included in the Thai 
national list of essential drugs, which is likely to explain the low prev-
alence of fixed dose combinations.
Our clinical audit suggests that, based on the 2015 guidelines, 
there is still room for improvement. The variation in adherence is 
likely due to the fact that the use of the guideline is at the discre-
tion of the treating physicians with no financial or other incentives 
provided to encourage adherence to guidelines. As physicians in 
Thailand do not require continuous medical education credits for 
relicensing, it may be possible that some physicians were unaware 
of the 2015 guidelines and thus being the explanation for the ob-
served non-compliance rather than therapeutic inertia.24 Our re-
sults provide evidence that medication adjustment consistent with 
recommendations in the 2015 Thai Hypertension Guideline was 
significantly associated with better hypertension control rate. In ad-
dition, our study found that those with more than one hypertensive 
medication were less likely to have their hypertension under control 
and only one patient received a fixed dose combination. Another 
study from Thailand suggested that higher number of antihyperten-
sive medications was associated with lower adherence.25 These two 
studies together with evidence from clinical trials suggest that fixed 
dose combination therapies may be helpful in the many patients re-
quiring more than one antihypertensive medication. This reduces 
the pill load for these patients of which many also receive other 
drugs for co-morbidities.26–28
Our data suggest that large hospitals had the lowest lost to 
follow-up rate while community hospitals and provincial hospitals 
higher rates. Similar to access to hypertension screening services, it 
is likely that provincial hospitals lose some patients due to larger dis-
tance to the hospitals.3 However, the community hospitals may lose 
patients due to insufficient communication.29,30 Reducing loss to fol-
low-up may be one way to achieve better hypertension control. Lost 
to follow-up may be attributable to low perception of self-risk reduc-
ing motivation for returning for follow-up blood pressure measure-
ment,31 as well as such things as long and discouraging waiting times 
for consultation and drug delivery to patients.32,33 Characterization 
of patients lost to follow-up will help identify high risk group and 
potentially mitigate against loss. Importantly, use of a unique patient 
ID with longitudinal follow-up whether in private or public hospital 
may help in tracing patients and avoid lost to follow-up. Currently, 
hospital IDs cannot connect to other hospitals. Ten percent of new 
cases entering the study already had a previous diagnosis of hy-
pertension from another hospital, thus streamlining of the referral 
system would help in transition of care of patients from one facility 
to the other, reducing loss of patients during the back and forth be-
tween different facilities 34
Compliance to hypertension guidelines and hypertension control 
rates varied across hospital size, with the bigger hospitals doing bet-
ter than the smaller community hospitals. This may be due to the 
organization of hypertension services between hospitals of different 
sizes across the country. Bigger hospitals have better infrastructure, 
more physicians and better access to specialists than smaller hos-
pitals and this may help explain our results.8 However, our findings 
are in contrast to one study that reported smaller Thai hospitals to 
have better blood pressure control than bigger provincial ones (77% 
vs 72%).14 A possible explanation for this is that the more complex 
cases were referred for treatment in bigger provincial hospitals 
which may also explain the lower compliance in provincial hospitals 
in our study.
Our study found dose adjustment to be especially import-
ant for hypertension control, but other factors may be considered 
to improve the overall hypertension control rates in Thailand.20 
Literature suggests that suboptimal control usually reflect existing 
programmatic challenges including suboptimal management, long 
waiting times for consultation and drug collection which encourage 
loss to follow-up.35,36 Reorganization services to include a multi-
disciplinary care team may be necessary.37 Delegation of duties of 
prescribing drugs to non-physician health care workers like nurses 
and pharmacists may help to reduce waiting times and improve con-
trol.38–40 In Thailand, there is evidence that reorienting services to 
have a more patient-centered approach, allowing for continuity of 
care and greater patient-provider communication, may be useful 
for hypertension control.41 Based on the results of this research, 
an application for including fixed dose combination pills in the na-
tional essential drug list has been submitted. The Thai Strategic and 
Technical Advisory Group for Hypertension, chaired by the Director-
General of the Department of Disease Control, has also approved a 
pilot implementation of simple treatment protocol and village health 
volunteer training that may pave the way for improved blood pres-
sure control.
The study has at least two limitations. We included only new 
cases entering treatment and thus the control rate may not apply 
Model 1 Model 2 Model 3
OR hypertension control at 
last visit (95%CI) p-value
OR hypertension control 
at last visit p-value
OR hypertension control 
at last visit p-value
Number of prescriptions
One Reference <.01
More than one 0.66 (0.51 to 0.85, p < .01
aConsistent with 2015 Thai Hypertension Guideline recommendations. 
bDid not receive appropriate number of medication based on baseline CVD risk. 
cDid not received medication adjustments when required. 
TABLE 5 (Continued)
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to cases already in long-term treatment. The long-term control rate 
is likely to be lower as according to the Thai 2018 MoPH statistics, 
only 42% of hypertensive patients in treatment had their BP con-
trolled.42 Secondly, we sampled from four regions of Thailand, with 
only 4 provincial (>120 beds) hospital and 4 large (90–120 bed) hos-
pitals included in the audit, which may limit overall generalizability 
to the whole country. It is likely that there may be more variability 
across provinces as Thai MoPH statistics demonstrated that hyper-
tension control rate in 2018 varied between 25% and 55% between 
provinces.43
5  |  CONCLUSIONS
This audit of 1406 newly registered hypertensive patients attend-
ing 16 Thai hospitals demonstrated that half of patients had their 
hypertension controlled at six months and around two thirds of 
newly diagnosed cases had their blood pressure controlled during 
their last reading over 1 year. In large (90–120 beds) hospitals, the 
control rate was as high as 71%. These results are not perfect and 
leave room for improvement by strengthening some components 
of hypertension management. Failure to comply with the guide-
lines for antihypertensive treatment regarding dose adjustment 
and loss to follow-up were highlighted as possible target areas to 
improve blood pressure control in Thailand. Continuous training of 
health care providers on updated treatment guidelines, as well as 
availability of fixed dose combinations and simplifying treatment 
protocols may help reducing treatment inertia and improve control 
rates further.
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